This Article Figures Only Full Text Full Text (PDF) All Versions of this Article: j.jacc.2006.08.031v1 48/11/2161    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lipsic, E. Articles by van Gilst, W. H. Search for Related Content PubMed PubMed Citation Articles by Lipsic, E. Articles by van Gilst, W. H.

STATE-OF-THE-ART PAPER

Protective Effects of Erythropoietin in Cardiac Ischemia

From Bench to Bedside

Erik Lipic, MD, PhD^_*,,_*, Regien G. Schoemaker, PhD^_*, Peter van der Meer, MD, PhD^_*,, Adriaan A. Voors, MD, PhD, Dirk J. van Veldhuisen, MD, PhD, FACC and Wiek H. van Gilst, PhD^_*,

^_*Clinical Pharmacology
Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

Manuscript received April 5, 2006; revised manuscript received August 10, 2006, accepted August 14, 2006.

^_* Reprint requests and correspondence: Dr. Erik Lipic, A. Deusinglaan 1, 9713 AV Groningen, the Netherlands (Email: e.lipsic{at}dz.nl).

Erythropoietin (EPO) is a hypoxia-induced hormone produced in the kidneys that stimulates hematopoiesis in the bone marrow. However, recent studies have also shown important nonhematopoietic effects of EPO. A functional EPO receptor is found in the cardiovascular system, including endothelial cells and cardiomyocytes. In animal studies, treatment with EPO during ischemia/reperfusion in the heart has been shown to limit the infarct size and the extent of apoptosis. In the longer term, EPO may promote ischemia-induced neovascularization, either by stimulating endothelial cells in situ or by mobilizing endothelial progenitor cells from bone marrow. The effects of EPO in the ischemic heart support the concept of EPO as a pleiotropic, tissue-protective agent for other organs expressing the EPO receptor. We recently performed a first randomized clinical study showing the safety and feasibility of EPO administration in patients with acute myocardial infarction. Future clinical studies are warranted to translate the beneficial effects of EPO from basic experiments to cardiac patients.

Abbreviations and Acronyms   CHF = chronic heart failure   CKD = chronic kidney disease   EPC = endothelial progenitor cell   EPO = erythropoietin   EPO-R = erythropoietin receptor   I/R = ischemia/reperfusion   LV = left ventricle/ventricular   MI = myocardial infarction   rhEPO = recombinant human erythropoietin

This article has been cited by other articles:

				Y. Wang, X. Hu, X. Xie, A. He, X. Liu, and J.-a. Wang Effects of mesenchymal stem cells on matrix metalloproteinase synthesis in cardiac fibroblasts Exp Biol Med, October 1, 2011; 236(10): 1197 - 1204. [Abstract] [Full Text] [PDF]

				S. S. Najjar, S. V. Rao, C. Melloni, S. V. Raman, T. J. Povsic, L. Melton, G. W. Barsness, K. Prather, J. F. Heitner, R. Kilaru, et al. Intravenous Erythropoietin in Patients With ST-Segment Elevation Myocardial Infarction: REVEAL: A Randomized Controlled Trial JAMA, May 11, 2011; 305(18): 1863 - 1872. [Abstract] [Full Text] [PDF]

				P. v. d. Meer and D. J. v. Veldhuisen 28 Anaemia Oxford Textbook of Heart Failure, January 1, 2011; 1(1): med-9780199577729-chapter - med-9780199577729-chapter. [Abstract] [Full Text]

				W. P. J. den Elzen, J. M. Willems, R. G. J. Westendorp, A. J. M. de Craen, G. J. Blauw, L. Ferrucci, W. J. J. Assendelft, and J. Gussekloo Effect of erythropoietin levels on mortality in old age: the Leiden 85-plus Study Can. Med. Assoc. J., December 14, 2010; 182(18): 1953 - 1958. [Abstract] [Full Text] [PDF]

				P. van der Meer, E. Lipsic, and D. J. van Veldhuisen Asialoerythropoietin to Protect the Failing Heart: Is it Possible to Run With the Hare and Hunt With the Hounds? J. Am. Coll. Cardiol., November 30, 2010; 56(23): 1959 - 1960. [Full Text] [PDF]

				A. A. Voors, A. M. S. Belonje, F. Zijlstra, H. L. Hillege, S. D. Anker, R. H. J. A. Slart, R. A. Tio, A. van 't Hof, J. W. Jukema, H. O. J. Peels, et al. A single dose of erythropoietin in ST-elevation myocardial infarction Eur. Heart J., November 1, 2010; 31(21): 2593 - 2600. [Abstract] [Full Text] [PDF]

				P. Ponikowski and E. A. Jankowska EPO's rescue mission in acute myocardial infarction: still more hopes than evidence Eur. Heart J., November 1, 2010; 31(21): 2577 - 2579. [Full Text] [PDF]

				J. G. F. Cleland, A. P. Coletta, A. Torabi, D. Ahmed, and A. L. Clark Clinical trials update from the European Society of Cardiology Meeting 2010: SHIFT, PEARL-HF, STAR-heart, and HEBE-III Eur J Heart Fail, November 1, 2010; 12(11): 1261 - 1264. [Abstract] [Full Text] [PDF]

				B. D. Westenbrink, W.-P. T. Ruifrok, A. A. Voors, R. G. Tilton, D. J. van Veldhuisen, R. G. Schoemaker, W. H. van Gilst, and R. A. de Boer Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure Cardiovasc Res, July 1, 2010; 87(1): 30 - 39. [Abstract] [Full Text] [PDF]

				A. D. Calvin, V. K. Somers, D. P. Steensma, J. A. Rio Perez, C. van der Walt, J. M. Fitz-Gibbon, C. G. Scott, and L. J. Olson Advanced heart failure and nocturnal hypoxaemia due to central sleep apnoea are associated with increased serum erythropoietin Eur J Heart Fail, April 1, 2010; 12(4): 354 - 359. [Abstract] [Full Text] [PDF]

				P. J. Wijkstra and D. J van Veldhuisen Central sleep apnoea: another important comorbidity in heart failure? Eur J Heart Fail, April 1, 2010; 12(4): 309 - 310. [Full Text] [PDF]

				S. Tamareille, N. Ghaboura, F. Treguer, D. Khachman, A. Croue, D. Henrion, A. Furber, and F. Prunier Myocardial reperfusion injury management: erythropoietin compared with postconditioning Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2035 - H2043. [Abstract] [Full Text] [PDF]

				P. van der Meer and D. J van Veldhuisen Anaemia and renal dysfunction in chronic heart failure Heart, November 1, 2009; 95(21): 1808 - 1812. [Full Text] [PDF]

				F. G. Hage, R. Venkataraman, G. J. Zoghbi, G. J. Perry, A. M. DeMattos, and A. E. Iskandrian The Scope of Coronary Heart Disease in Patients With Chronic Kidney Disease J. Am. Coll. Cardiol., June 9, 2009; 53(23): 2129 - 2140. [Abstract] [Full Text] [PDF]

				G. Y. Oudit and J. M. Penninger Cardiac regulation by phosphoinositide 3-kinases and PTEN Cardiovasc Res, May 1, 2009; 82(2): 250 - 260. [Abstract] [Full Text] [PDF]

				J. L. Mehta Erythropoietin in cardioprotection: does it have a future or is it all in the past? Cardiovasc Res, September 1, 2008; 79(4): 549 - 550. [Full Text] [PDF]

				E. Lipsic, B. D. Westenbrink, P. van der Meer, P. van der Harst, A. A. Voors, D. J. van Veldhuisen, R. G. Schoemaker, and W. H. van Gilst Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit Eur J Heart Fail, January 1, 2008; 10(1): 22 - 29. [Abstract] [Full Text] [PDF]